Great news for Irish EB research thanks to your support.

DEBRA Ireland-supported research gets major boost with investment by Amryt Pharma to develop treatments for people living with EB.

DEBRA Ireland is delighted to share the great news of UCD Charles Institute’s collaboration with Amryt Pharma in the development of a polymer to treat patients with recessive dystrophic epidermolysis bullosa (RDEB). DEBRA Ireland has supported Professor Wenxin Wang and his team including Dr Lara Cutlar, a post-doctoral fellow at UCD, in their research of this technology for years.

Amryt is an Irish bio-pharma company focused on treatments that help improve the lives of people with rare and orphan diseases. The UCD Charles Institute has just signed an in-license agreement with Amryt Pharma to develop a platform for the delivery of gene therapy. The high-branched poly β-amino ester (HPAE) polymer is showing positive potential for the delivery of gene therapy in the skin where the defective collagen VII protein is present.

DEBRA Ireland’s Head of Research , Dr Sinead Hickey commented, “We are delighted to see the fruits of this research move a step closer to a novel treatment for patients with RDEB. This technology is in the early stages of development, but if successful, could be ground breaking for the treatment of EB. This success is down to the continued support of our donors.”

For more information please see below

Silicon Republic

Irish Times